The risk of postpartum hemorrhage when lowering the oxytocin dose in planned cesarean section, a pilot study.

Oxytocin Oxytocin dose Planned cesarean section Postpartum hemorrhage Uterine atony Uterine contractility

Journal

Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives
ISSN: 1877-5764
Titre abrégé: Sex Reprod Healthc
Pays: Netherlands
ID NLM: 101530546

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 13 06 2020
revised: 17 05 2021
accepted: 01 06 2021
pubmed: 27 6 2021
medline: 29 10 2021
entrez: 26 6 2021
Statut: ppublish

Résumé

Oxytocin is the drug of choice in preventing postpartum hemorrhage (PPH). The aim was to compare the peroperative- and total blood loss within two hours and PPH after planned cesarean section (CS) when receiving 2.5 IU vs 5.0 IU of oxytocin in different risk groups for PPH. A pilot study including 927 women undergoing planned CS where women receiving 2.5 IU of oxytocin were compared to women receiving 5.0 IU of oxytocin. Data comparing peroperative blood loss, total blood loss within two hours and PPH were analyzed. The women receiving 2.5 IU of oxytocin had a slightly higher peroperative blood loss, compared to the 5.0 IU group (476 ml vs 426 ml, p = 0.029). The total blood loss two hours after surgery showed no significant difference between the groups (626 ml vs 595 ml, p = 0.230). In the 2.5 IU group 13% had a blood loss ≥ 1000 ml vs 10% in the 5 IU group (aOR 1.64, 95% CI = 1.05-2.56). When the women considered to be at high risk for postpartum hemorrhage were excluded, we found no difference in the likelihood for postpartum hemorrhage between the groups (aOR 1.13, 95% CI = 0.64-1.99). Women undergoing planned CS and receiving 2.5 IU of oxytocin had a slightly higher risk for postpartum hemorrhage in this study. However, a lower dose of 2.5 IU of oxytocin seems to be a safe option in planned CS for women without known risk factors for postpartum hemorrhage, but further research is needed to confirm these findings.

Identifiants

pubmed: 34174496
pii: S1877-5756(21)00048-3
doi: 10.1016/j.srhc.2021.100641
pii:
doi:

Substances chimiques

Oxytocics 0
Oxytocin 50-56-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100641

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Valerie Stålberg (V)

Department of Obstetrics and Gynecology in Norrköping and Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Sweden.

Ann Josefsson (A)

Department of Obstetrics and Gynecology in Linköping and Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Sweden.

Marie Bladh (M)

Department of Obstetrics and Gynecology in Linköping and Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Sweden.

Caroline Lilliecreutz (C)

Department of Obstetrics and Gynecology in Linköping and Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Sweden. Electronic address: caroline.lilliecreutz@regionostergotland.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH